Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monocentric prospective randomized controlled open phase IV study to explorate the mechanismen of the synergetic effect of the Crateagus -Extract WS 1442 in addition to endurance training related to quality of life of patients with limited physical potential caused by cardiovascular disease (Heart Failure Stade NYHA II).

Trial Profile

Monocentric prospective randomized controlled open phase IV study to explorate the mechanismen of the synergetic effect of the Crateagus -Extract WS 1442 in addition to endurance training related to quality of life of patients with limited physical potential caused by cardiovascular disease (Heart Failure Stade NYHA II).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crataegus (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Dr. Willmar Schwabe Pharmaceuticals

Most Recent Events

  • 12 Jul 2012 Additional trial identifier 2009-111 identified as reported by German Clinical Trials Register.
  • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register DRKS00000259).
  • 25 Aug 2011 Status changed from recruiting to completed as reported by German Clinical Trials Register

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top